Inflammasome Therapeutics, Inc.

NEWTON, MA · Biotech · Private

Small-molecule therapeutics targeting inflammasome activation pathways for neurodegenerative and metabolic diseases

Claim this profile

Follows are private to you and power your alerts

Updated · inflam.com

Sector
Biotech
Headquarters
NEWTON, MA
Latest Form D
$13.2M, May 2026
Total capital
$18.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$18.4M
3 Form D · last May 2026
6 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
2 pending · first 2023
Rank in peer group#481 of 1449

Capital timeline

2023202420252026FEDERAL ↑EQUITY ↓Cumulative $18.4M1st Form D$2.8M2nd Form D$2.5M3rd Form D$13.2M
2023202420252026FEDERAL ↑EQUITY ↓Cumulative $18.4M1st Form D$2.8M3rd Form D$13.2M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$13.2M
  • Private capital raisedForm D · SEC · 2nd filing$2.5M
  • Private capital raisedForm D · SEC · 1st filing$2.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Babur B. LateefDirectorNamed in SEC Form D filings
  • Balamurali AmbatiDirectorNamed in SEC Form D filings
  • Chaniyilparampu N. RamchandDirectorNamed in SEC Form D filings
  • Jayakrishna AmbatiExecutive Officer, DirectorNamed in SEC Form D filings
  • Joon LeeDirectorNamed in SEC Form D filings
  • Mary WeberDirectorNamed in SEC Form D filings
Show all 8 people
  • Napoleone FerraraDirectorNamed in SEC Form D filings
  • Paul AshtonExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 3
  • PendingImplantUSPTOApplication 18375713
  • GrantedIntraocular InjectorUSPTOUS 11,819,454
  • PendingImplantUSPTOApplication PCTUS2023075695

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .